Recent advances in de novo CD5+ diffuse large B cell lymphoma

American Journal of Hematology

Volumn 88, Issue 9, 2013, Pages 798-802

  Jain, Preetesh ^a   Fayad, Luis E ^a   Rosenwald, Andreas ^b   Young, Ken H ^a   O'Brien, Susan ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD5 ANTIGEN; LACTATE DEHYDROGENASE; RITUXIMAB;

ANTIGEN EXPRESSION; B LYMPHOCYTE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM; CHROMOSOME ABERRATION; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; EVENT FREE SURVIVAL; EXTRACELLULAR MATRIX; GENE EXPRESSION; GIANT CELL; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; INCIDENCE; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; MEDLINE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SOMATIC MUTATION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE; UPREGULATION;

AGE FACTORS; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD5; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; GENE EXPRESSION; HUMANS; L-LACTATE DEHYDROGENASE; LYMPHOMA, LARGE B-CELL, DIFFUSE; NEOPLASM STAGING; SEX FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84882727257     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23467     Document Type: Review

References (54)

1. Campo E, Swerdlow SH, Harris NL. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011;117:5019-5032.
2. Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 2006;24:995-1007.
3. Rosenwald A, Wright G, Chan WC. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-1947.
4. Lenz G, Wright GW, Emre NC. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 2008;105:13520-13525.
5. Lenz G, Wright G, Dave SS. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359:2313-2323.
6. Alizadeh AA, Eisen MB, Davis RE. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511.
7. Wright G, Tan B, Rosenwald A. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003;100:9991-9996.
8. Harada S, Suzuki R, Uehira K. Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5- with CD10+ groups may constitute clinically relevant subtypes. Leukemia 1999;13:1441-1447.
9. Matolcsy A, Chadburn A, Knowles DM. De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct. Am J Pathol 1995;147:207-216.
10. Yamaguchi M, Ohno T, Oka K. De novo CD5-positive diffuse large B-cell lymphoma: clinical characteristics and therapeutic outcome. Br J Haematol 1999;105:1133-1139.
11. Yamaguchi M, Seto M, Okamoto M. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 2002;99:815-821.
12. Yamaguchi M, Nakamura N, Suzuki R. De novo CD5+ diffuse large B-cell lymphoma: Results of a detailed clinicopathological review in 120 patients. Haematologica 2008;93:1195-1202.
13. Maeshima AM, Taniguchi H, Nomoto J. Secondary CD5+ diffuse large B-cell lymphoma not associated with transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (Richter syndrome). Am J Clin Pathol 2009;131:339-346.
14. Padilla O, Calvo J, Vila JM. Genomic organization of the human CD5 gene. Immunogenetics 2000;51:993-1001.
15. Youinou P, Jamin C, Lydyard PM. CD5 expression in human B-cell populations. Immunol Today 1999;20:312-316.
16. Berland R, Wortis HH. Origins and functions of B-1 cells with notes on the role of CD5. Annu Rev Immunol 2002;20:253-300.
17. Hippen KL, Tze LE, Behrens TW. CD5 maintains tolerance in anergic B cells. J Exp Med 2000;191:883-890.
18. Dalloul A. CD5: a safeguard against autoimmunity and a shield for cancer cells. Autoimmun Rev 2009;8:349-353.
19. Griffin DO, Holodick NE, Rothstein TL. Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+ CD27+ CD43+ CD70. J Exp Med 2011;208:67-80.
20. Lankester AC, van Schijndel GM, Cordell JL. CD5 is associated with the human B cell antigen receptor complex. Eur J Immunol 1994;24:812-816.
21. Gary-Gouy H, Bruhns P, Schmitt C. The pseudo-immunoreceptor tyrosine-based activation motif of CD5 mediates its inhibitory action on B-cell receptor signaling. J Biol Chem 2000;275:548-556.
22. Gary-Gouy H, Harriague J, Bismuth G. Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production. Blood 2002;100:4537-4543.
23. Gary-Gouy H, Sainz-Perez A, Marteau JB. Natural phosphorylation of CD5 in chronic lymphocytic leukemia B cells and analysis of CD5-regulated genes in a B cell line suggest a role for CD5 in malignant phenotype. J Immunol 2007;179:4335-4344.
24. Tagawa H, Suguro M, Tsuzuki S Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. Blood 2005;106:1770-1777.
25. Hans CP, Weisenburger DD, Greiner TC. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-282.
26. Dronca RS, Jevremovic D, Hanson CA. CD5-positive chronic B-cell lymphoproliferative disorders: Diagnosis and prognosis of a heterogeneous disease entity. Cytom B Clin Cytom 2010;78 (Suppl 1):S35-S41.
27. Visco C, Li Y, Xu-Monette ZY. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia, 2012;26:2103-2113.
28. Manazza AD, Bonello L, Pagano M. Follicular origin of a subset of CD5+ diffuse large B-cell lymphomas. Am J Clin Pathol 2005;124:182-190.
29. Kobayashi T, Yamaguchi M, Kim S. Microarray reveals differences in both tumors and vascular specific gene expression in de novo CD5+ and CD5- diffuse large B-cell lymphomas. Cancer Res 2003;63:60-66.
30. Suguro M, Tagawa H, Kagami Y. Expression profiling analysis of the CD5+ diffuse large B-cell lymphoma subgroup: development of a CD5 signature. Cancer Sci 2006;97:868-874.
31. Miyazaki K, Yamaquchi M, Imai H, et al. Gene expression profiling of diffuse large B cell lymphomas supervised by CD5 expression. ASH annual meeting abstracts, 2010;116:4164-874.
32. Karnan S, Tagawa H, Suzuki R. Analysis of chromosomal imbalances in de novo CD5-positive diffuse large-B-cell lymphoma detected by comparative genomic hybridization. Genes Chromosomes Cancer 2004;39:77-81.
33. Tagawa H, Tsuzuki S, Suzuki R. Genome-wide array-based comparative genomic hybridization of diffuse large B-cell lymphoma: comparison between CD5-positive and CD5-negative cases. Cancer Res 2004;64:5948-5955.
34. Ota A, Tagawa H, Karnan S. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res 2004;64:3087-3095.
35. Calin GA, Sevignani C, Dumitru CD. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004;101:2999-3004.
36. Yoshioka T, Miura I, Kume M. Cytogenetic features of de novo CD5-positive diffuse large B-cell lymphoma: chromosome aberrations affecting 8p21 and 11q13 constitute major subgroups with different overall survival. Genes Chromosomes Cancer 2005;42:149-157.
37. Martinez-Climent JA, Vizcarra E, Sanchez D. Loss of a novel tumor suppressor gene locus at chromosome 8p is associated with leukemic mantle cell lymphoma. Blood 2001;98:3479-3482.
38. Kaneko H, Shimura K, Horiike S. Cytogenetic analysis of de novo CD5-positive diffuse large B-cell lymphoma. Asia Pac J Clin Oncol 2011;7:346-350.
39. Nakamura N, Abe M. Histogenesis of CD5-positive and CD5-negative B-cell neoplasms on the aspect of somatic mutation of immunoglobulin heavy chain gene variable region. Fukushima J Med Sci 2003;49:55-67.
40. Nakamura N, Nakamura S, Yamaguchi M. CD5+ diffuse large B-cell lymphoma consists of germline cases and hypermutated cases in the immunoglobulin heavy chain gene variable region. Int J Hematol 2005;81:58-61.
41. Kroft SH, Howard MS, Picker LJ. De novo CD5+ diffuse large B-cell lymphomas. A heterogeneous group containing an unusual form of splenic lymphoma. Am J Clin Pathol 2000;114:523-533.
42. Niitsu N, Okamoto M, Tamaru JI. Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma. Ann Oncol 2010;21:2069-2074.
43. Westin J, McLaughlin P. De novo CD5+ diffuse large B-cell lymphoma: a distinct subset with adverse features, poor failure-free survival and outcome with conventional therapy. Leuk Lymphoma 2010;51:161-163.
44. A predictive model for aggressive non-Hodgkin's lymphoma. The international non-hodgkin's lymphoma prognostic factors project. N Engl J Med 1993;329:987-994.
45. Miyazaki K, Yamaguchi M, Suzuki R. CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann Oncol 2011;22:1601-1607.
46. Ennishi D, Takeuchi K, Yokoyama M. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol 2008;19:1921-1926.
47. Iqbal J, Neppalli VT, Wright G. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 2006;24:961-968.
48. Salles G, de Jong D, Xie W. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood 2011;117:7070-7078.
49. Dong HY, Gorczyca W, Liu Z. B-cell lymphomas with coexpression of CD5 and CD10. Am J Clin Pathol 2003;119:218-230.
50. Mao Z, Quintanilla-Martinez L, Raffeld M. IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution. Am J Surg Pathol 2007;31:1605-1614.
51. Rossi D, Spina V, Deambrogi C. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood 2011;117:3391-3401.
52. Shimada K, Kinoshita T, Naoe T. Presentation and management of intravascular large B-cell lymphoma. Lancet Oncol 2009;10:895-902.
53. Imai H, Shimada K, Shimada S. Comparative clinicopathological study of primary CNS diffuse large B-cell lymphoma and intravascular large B-cell lymphoma. Pathol Int 2009;59:431-437.
54. Hyo R, Tomita N, Takeuchi K. The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma. Hematol Oncol 2010;28:27-32.